SecSonar.com

InflaRx N.V. (IFRX)

InflaRx N.V. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

InflaRx N.V. (IFRX) is a Biotechnology company based in DE with a market capitalization of $175.9M. Revenue declined 82.3% year-over-year and free cash flow was negative at -$38.9M. This page tracks IFRX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

DE · 74 employees · IPO Nov 7, 2017

Valuation

Valuation & price

$2.78 · as of May 26, 2026 · 1.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

—

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$2.61$1.71$0.81Jul 25Dec 25Jul 26Jul 7, 25$0.82Jul 9, 25$0.89Jul 11, 25$0.88Jul 15, 25$0.81Jul 17, 25$0.87Jul 21, 25$0.86Jul 23, 25$0.86Jul 25, 25$0.90Jul 29, 25$0.87Jul 31, 25$0.91Aug 4, 25$0.89Aug 6, 25$0.84Aug 11, 25$0.82Aug 13, 25$0.82Aug 15, 25$0.86Aug 19, 25$0.88Aug 21, 25$0.90Aug 25, 25$0.92Aug 27, 25$1.00Aug 29, 25$1.60Sep 3, 25$1.73Sep 5, 25$1.65Sep 9, 25$1.53Sep 11, 25$1.47Sep 16, 25$1.14Sep 18, 25$1.37Sep 22, 25$1.35Sep 24, 25$1.36Sep 26, 25$1.30Sep 30, 25$1.34Oct 2, 25$1.38Oct 6, 25$1.51Oct 8, 25$1.47Oct 10, 25$1.38Oct 14, 25$1.28Oct 16, 25$1.24Oct 21, 25$1.36Oct 23, 25$1.22Oct 27, 25$1.66Oct 29, 25$1.38Oct 31, 25$1.46Nov 4, 25$1.27Nov 6, 25$1.20Nov 10, 25$1.58Nov 12, 25$1.46Nov 14, 25$1.35Nov 18, 25$1.27Nov 20, 25$1.15Nov 25, 25$1.18Nov 28, 25$1.26Dec 2, 25$0.99Dec 4, 25$1.10Dec 8, 25$1.06Dec 10, 25$1.05Dec 12, 25$1.05Dec 16, 25$1.04Dec 18, 25$1.06Dec 22, 25$1.12Dec 24, 25$1.14Dec 29, 25$1.02Jan 2, 26$1.09Jan 6, 26$1.17Jan 8, 26$1.09Jan 12, 26$1.02Jan 14, 26$1.07Jan 16, 26$1.00Jan 21, 26$1.00Jan 23, 26$1.01Jan 27, 26$0.97Jan 29, 26$0.92Feb 2, 26$0.97Feb 4, 26$0.84Feb 9, 26$0.86Feb 11, 26$0.85Feb 13, 26$0.86Feb 18, 26$0.88Feb 20, 26$0.89Feb 24, 26$0.88Feb 26, 26$0.93Mar 2, 26$0.92Mar 4, 26$0.92Mar 6, 26$0.97Mar 10, 26$0.93Mar 12, 26$0.98Mar 17, 26$0.91Mar 19, 26$0.91Mar 23, 26$0.97Mar 25, 26$0.94Mar 27, 26$0.91Mar 31, 26$0.89Apr 2, 26$0.91Apr 7, 26$0.97Apr 9, 26$1.03Apr 13, 26$1.07Apr 15, 26$1.21Apr 17, 26$1.59Apr 22, 26$1.60Apr 24, 26$1.48Apr 28, 26$1.67Apr 30, 26$2.07May 4, 26$2.13May 6, 26$2.50May 8, 26$2.58May 12, 26$2.43May 14, 26$2.38May 18, 26$2.50May 20, 26$2.44May 22, 26$2.61May 28, 26$2.38Jun 1, 26$2.28Jun 3, 26$2.06Jun 5, 26$1.84Jun 9, 26$1.66Jun 11, 26$1.68Jun 15, 26$1.62Jun 17, 26$1.82Jun 22, 26$1.90Jun 24, 26$1.93Jun 26, 26$1.92Jul 2, 26$2.24
$0.8052-week range$2.74
Loading valuation history…

Fundamentals

Key fundamentals

$175.9M

Market cap

-82.3%

Revenue growth (YoY)

-24677.9%

Gross margin

-$38.9M

Free cash flow (USD)

-$45.5M

Net debt

Net cash position

14.2%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$0.00FY 2017$0.00FY 2018$0.00FY 2019$0.00FY 2020$0.00FY 2021$0.00FY 2022$0.00FY 2023$63.1KFY 2024$165.8KFY 2025$29.3K
$0$29.3K

Free cash flow by year

2016 → 2025

FY 2016$-5.0MFY 2017$-12.3MFY 2018$-24.5MFY 2019$-43.8MFY 2020$-36.6MFY 2021$-40.0MFY 2022$-33.9MFY 2023$-37.9MFY 2024$-48.6MFY 2025$-34.0M
-$5M-$34M

Gross margin by year

2023 → 2025

FY 2023-743.7%FY 2024-1900.8%FY 2025-24677.9%
-743.7%-24677.9%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed May 6, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingRegulatory UpdateJun 30, 2026Filing
  • 6-K filingUnderwriting AgreementMay 7, 2026Filing
  • Annual reportAnnual Report FiledMay 6, 2026Filing
  • 6-K filingCorporate PresentationMay 6, 2026Filing
  • Annual reportAnnual Report FiledMay 4, 2026Filing
  • 6-K filingRegulatory UpdateApr 28, 2026Filing
  • Annual reportAnnual Report FiledApr 23, 2026Filing
  • Annual reportAnnual Report FiledApr 9, 2026Filing
  • Annual reportAnnual Report FiledApr 2, 2026Filing

Questions

Frequently asked questions

What is InflaRx N.V.'s market cap?

InflaRx N.V. (IFRX) has a market capitalization of $175.9M.

What is IFRX's P/E ratio?

A meaningful P/E ratio is not available for IFRX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

Are insiders buying IFRX stock?

SEC Form 4 filings show no open-market insider buys at InflaRx N.V. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

AVTX

Avalo Therapeutics, Inc.

$179.1M

PLX

Protalix BioTherapeutics, Inc.

$170.4M

IPHA

Innate Pharma S.A.

$182.2M

PRQR

ProQR Therapeutics N.V.

$168.6M

SRZN

Surrozen, Inc.

$184.8M

SPRO

Spero Therapeutics, Inc.

$163.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.